Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 5/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7027366 | 0.93 | PDPK1 (0.47) | ABCB1ABCG2MAPTNPSR1TDP1 | |
| SCHEMBL7028113 | 0.93 | MAPT (0.43) | ABCB1ABCG2CXCL12MAPTNPSR1 | |
| SCHEMBL7030660 | 0.92 | TDP1 (0.50) | ABCB1ABCG2CXCL12MAPTNPSR1 | |
| SCHEMBL7029104 | 0.91 | TP53 (0.43) | ABCB1ABCG2CXCL12MAPTNPSR1 | |
| SCHEMBL7026486 | 0.91 | MAPT (0.53) | ABCB1MAPTNPSR1MAOBMAOA | |
| SCHEMBL744120 | 0.91 | ABCB1 (0.52) | ABCB1ABCG2CXCL12CXCR4MAPT | |
| SCHEMBL7025976 | 0.91 | ABCB1 (0.51) | ABCB1CXCL12MAPTNPSR1MAOB | |
| SCHEMBL7028278 | 0.90 | ABCB1 (0.51) | ABCB1ABCG2MAPTNPSR1MAOB | |
| SCHEMBL7027458 | 0.89 | ABCB1 (0.41) | ABCB1ABCG2MAPTNPSR1TDP1 | |
| SCHEMBL7028325 | 0.88 | ABCB1 (0.48) | ABCB1ABCG2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | CDK6, CDK5, CDK4 | ABCB1 2307/4885ABCG2 2761/4885CXCL12 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.